… received orphan drug designation (ODD) from the FDA and European Medicines Agency (EMA). QR-411 targets the … QR-010 is designed to be self-administered via an optimized eFlow ® Nebulizer (PARI Pharma GmbH). eFlow ® is a … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… (0.72) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
ProQR is accelerating the development of its Axiomer® RNA base-editing technology platform across multiple therapeutic areas and will provide an update on first targets in H2 2022
Company plans to discuss findings from sepofarsen Illuminate trial w
… (0.25) For these periods the potential exercise of share options is not included in the diluted earnings per share as … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal. … Premium Equity settled Employee Benefit Reserve Option premium on convertible loan Translation Reserve …
… a public offering in October that will allow us to fund operations into 2022, well beyond the expected top-line … of $5.50 per share with full exercise of underwriters’ option to purchase 1,363,636 additional ordinary shares. Net … financial statements, the potential exercise of share options is not included in the diluted earnings per share …
… $15.75 per share including full exercise of underwriters’ option to purchase 862,500 additional ordinary shares. Gross … oligonucleotide QR-110 for treatment of inherited retinal dystrophy in adults and children with LCA10 ○ Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Presented at …
… robust clinical proof of concept in the early phase of our development program. I also want to thank the patients that … LCA10 compound heterozygous patient cells and homozygous optic cups in a dose dependent manner. Based on this data, … into pre-clinical development for the treatment of dystrophic epidermolysis bullosa (DEB). QR-313 is an RNA …
… financial statements, the potential exercise of share options is not included in the diluted earnings per share … Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in …
… 10 patients. David M. Rodman, MD was appointed as Chief Development Strategy Officer of ProQR, and will lead the … 10 (LCA 10) patients. The trial, named PQ-110-001, is an open-label trial that will include approximately 6 children … 6 adults (≥ 18 years) that have LCA 10 due to one or two copies of the p.Cys998X mutation. During the trial, patients …